Dr Jennifer Snaith
Conjoint Lecturer
FRACP, MBBS (Hons), BMedSci
Medicine & Health
School of Clinical Medicine
Dr Jennifer Snaith is an Endocrinologist and Research Fellow based at the Garvan Institute of Medical Research where she conducts clinical trials in type 1 diabetes as part of the AUSTAG group. Her career mission is to improve the lives of people living with type 1 diabetes through clinical service, advocacy and innovative research.
She is a Staff Specialist Endocrinologist at St Vincent's Hospital, and established with her team (Marhava/Lum/Higgins), the Diabetes in Youth (DIY) service in 2021. Her research activities are clinically based and relate to type 1 diabetes, insulin resistance, adjunctive therapies and cardiometabolic risk.
During her PhD candidature (primary supervisor Greenfield) Dr Snaith conducted the INTIMET study (INsulin resistance in type 1 diabetes managed with METformin) and was a recipient of the National Health and Medical Research Council (NHMRC) Post Graduate Scholarship, and Diabetes Australia top up scholarship. The INTIMET study was a placebo controlled randomised controlled clinical examining the impact of metformin on hepatic and muscle insulin resistance, assessed using hyperinsulinaemic euglycaemic clamps.
The RESET1 study (Reducing Cardiometabolic Risk with Semaglutide in Type 1 Diabetes) is the second clinical trial from the AUSTAG group. Snaith was awarded the Diabetes Australia Coghlan Award for Emerging Researchers, and the Rebecca Davies Fellowship from JDRF Australia to conduct this randomised placebo controlled clinical trial to examine the effect of semaglutide on cardiovascular risk in adults with type 1 diabetes. Trial registration:https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=386649&isReview=true
The TIRTLE study (Tirzepatide in Type 1 Diabetes: Cardiometabolic Effects) is a tirzepatide in type 1 diabetes placebo controlled trial (due for completion Dec 2024). Trial registration:https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=386985&isReview=true
Prof Jerry Greenfield and Dr Snaith established the Garvan Institute 'Australian Type 1 Diabetes Mellitus Adjuncts Group' (AUSTAG). The AUSTAG mission is to prolong the life of Australians living with type 1 diabetes by preventing cardiovascular disease through novel repurposing of cardioprotective medications. AUSTAG specialise in the conduct of clinical trials in type 1 diabetes. These studies include detailed mechanistic studies, to phenotype metabolic health in type 1 diabetes, and the physiological impacts of adjunctive therapies on cardiometabolic health in type 1 diabetes.
E-mail
- Publications
- Awards
- Grants
- Research Activities
- Engagement
- Teaching and Supervision
- Media
2024 - Australian Diabetes Society Lindsey Baudinet Rising Star Award in Type 1 Diabetes Research
2023 - Diabetes Australia Coghlan Award, for project 'Reducing Cardiometabolic Risk with Semaglutide in Type 1 Diabetes (RESET1)'
2022 - JDRF Rebecca Davies Fellowship
2022 - Australian Diabetes Society Clinical Young Investigator's Award
2021 - UNSW ARC Postgraduate Council Research Student Award
2020 - UNSW Visualise Your Thesis (Runner Up)
2020- NHMRC Post Graduate Scholarship
2020- NHMRC/Diabetes Australia co-funding award
2019- UNSW University Post Graduate Award
2018 - Joan Waugh Scholarship for academic excellence and leadership potential
2018 - Westmead Association Tracey Robinson Registrar Award for Excellence in Teaching
2017 - Westmead Association Advanced Trainee of the Year
2015 - WestmeadAssociation Tracey Robinson Registrar Award for Excellence in Teaching
2007 - University of Sydney Exchange Scholarship
2005 - Medical Science Scholarship
2024
- St Vincent’s Clinic Foundation Annual Grant $50,000,Snaith, JR (CI-A), Frampton R, Samocha-Bonet D, Greenfield JR, A Phase II study examining the effects of adjunctive tirzepatide on weight, metabolism and cardiovascular risk in adults with type 1 diabetes and obesity (the TIRTLE study)
- Australian Diabetes Society Lindsey Baudinet Rising Star in Type 1 Diabetes Award $20,000,Snaith JR (CI-A), Towards combo therapy: Tirzepatide for weight, metabolism and CV risk in adults with T1D and obesity (a phase II trial)'.
- MRFF 2023 TTRA – Cardiovascular Disease and Diabetes Mechanisms $916,315:Greenfield JR, Snaith JR (CI-B), Repurposed Semaglutide to Bridgethe T1DCardiovascular Risk Gap
2023
- Diabetes Australia Coghlan Award $150,000,Snaith JR (CI-A), Reducing Cardiometabolic Risk with Semaglutide in Type 1 Diabetes (RESET1)
2022
- JDRF Rebecca Davies Fellowship $142,500,Snaith JR (CI-A), Reducing Cardiometabolic Risk with Semaglutide in Type 1 Diabetes (RESET1)
- University of New South Wales Infrastructure Grant $200,651,Samocha-Bonet D, Snaith JR (CI-B), Greenfield JR, Chen R, Danta M, Jabbour A, Lim E, Patel S. BodPod and Q-NRG for extensive metabolic phenotyping
2021
- St Vincent’s Curran Foundation Endowment Grant $10,930,Snaith JR (CI-A), ‘Introducing rapid point of care HbA1c (Haemoglobin A1c) tests to SVH diabetes clinics’
- Cardiac, Vascular and Metabolic Medicine Theme Networking Seed Grant $30,000,Snaith JR (CI-A), Liu Z, Lovell N, Greenfield JR, ‘A novel online tool to diagnose double diabetes using biomarkers: towards cardiovascular risk reduction by personalised adjunctive treatment of insulin resistance in type 1 diabetes’
2020
- St Vincent’s Clinic Foundation Tancred Grant $50,000,Greenfield JR, Snaith J (CI-B), Holmes-Walker J, Girgis C, ‘INTIMET – Insulin Resistance in Type 1 Diabetes Managed with Metformin’
2019
- Diabetes Australia Millennium Grant (Type 1 Diabetes) $150,000,Greenfield JR, Snaith J (CI-B), Holmes Walker JR, Girgis C, Samocha-Bonet D, ‘Phenotypic Characterisation of Insulin-Sensitive and Insulin-Resistant Adults with Type 1 Diabetes’
My Research Supervision
UNSW PhD
- Dr R.Frampton: The Incretin Signature and the Role ofSemaglutide in Type 1 Diabetes
UNSW Medicine Honours
- J.Yang: Repurposing Adjunctive Therapies in Type 1 Diabetes: APatient Experience Survey
Previous research supervision:
UNSW Medicine Honours (B.Lamaro): An Unmet Needs Assessment in Type 1 Diabetes Mellitius: Rationale for Adjunctive Therapies?